Measured by the ability of the immobilized protein to enhance the adhesion of Saos‑2 human osteosarcoma cells to human Fibronectin. Measured by the ability of the immobilized protein to enhance the adhesion of Saos‑2 human osteosarcoma cells to human Fibronectin (0.5 μg/mL, Catalog #
4305-FNB). The ED50 for this effect is 2.5‑10 μg/mL.
Mouse myeloma cell line, NS0-derived human Syndecan-1/CD138 protein Gln18-Glu251, with a C-terminal 6-His tag
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
24.9 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Syndecan-1, designated CD138, is a dimeric type I transmembrane (TM) protein that belongs to the syndecan family of Type 1 transmembrane proteins (1, 2). The four syndecan family members are major carriers of heparan sulfate (HS) and chondroitin sulfate glycosaminoglycans (GAGs) that have different expression patterns and extracellular sequences. Syndecan-1 forms weak non-covalent homodimers, or heterodimers with Syndecan-2 or -3, through interactions of the transmembrane domain (3). It is synthesized as a 310 amino acid (aa) precursor with a 17 aa signal sequence, a 234 aa extracellular domain (ECD) that includes three closely-spaced consensus Ser-Gly HS attachment sites near the N-terminus, a 25 aa TM segment, and a 34 aa cytoplasmic region that includes a PDZ binding motif with a tyrosine phosphorylation site. The ECD is variably modified by GAGs, producing molecular weights of 120 - 200 kDa for native Syndecan-1. Soluble forms are shed via proteolytic cleavage. Human Syndecan-1 ECD shares 65 - 71% aa identity with the ECD of rat, mouse, canine, equine and bovine Syndecan-1. Syndecan-1 shows highest expression on epithelial cells such as keratinocytes, and terminally differentiated B cells such as plasma cells (4, 5). It aids wound healing in skin, cornea, and heart following myocardial infarction by promoting re-epithelialization, migration, and collagen deposition (4 - 8). It binds chemokines, creating chemotactic gradients when shed, but also binds and modulates integrins to control the influx of leukocytes (5, 7, 9). The net effect is to allow, but limit, inflammation. In myeloma and other cancers, shedding of Syndecan-1 can facilitate growth, angiogenesis and metastasis (10 - 12). Growth factors, such as FGFs and HGF, bind GAG chains and use Syndecan-1 as a coreceptor (12, 13). The GAG chains may also be used by a variety of viruses and bacteria for cell adhesion and uptake (4).
Tkachenko, E. et al. (2005) Circ. Res. 96:488.
Mali, M. et al. (1990) J. Biol. Chem. 265:6884.
Dews, I.C. and K.R. MacKenzie (2007) Proc. Natl. Acad. Sci. USA 104:20782.
Fears, C.Y. and A. Woods (2006) Matrix Biol. 25:443.
Stepp, M.A. et al. (2002) J. Cell Sci. 115:4517.
Ojeh, N. et al. (2008) J. Invest. Dermatol. 128:26.
Stepp, M.A. et al. (2007) J. Cell Sci. 120:2851.
Vanhoutte, D. et al. (2007) Circulation 115:475.
Li, Q. et al. (2002) Cell 111:635.
Beauvais, D.M. et al. (2009) J. Exp. Med. 206:691.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Recombinant Human Syndecan-1 Protein, CF and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.